Combined targeted therapy and immunotherapy for cancer treatment

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Monotherapies using targeted therapies or immunotherapies often yield limited or short-term responses in malignancies.
• Targeted therapies inhibiting oncogenic signaling or angiogenesis can potentially enhance anti-tumor immune responses.
• Understanding these interactions is crucial for developing effective combination strategies.

Purpose of the Study:

• To review recent combinations of targeted therapies and immunotherapies.
• To explore the mechanisms by which targeted therapies influence anti-tumor immunity.
• To identify clinical challenges associated with these combined treatment strategies.

Main Methods:

• Literature review of recent studies on targeted therapy and immunotherapy combinations.
• Analysis of preclinical and clinical data on immune response modulation.
• Synthesis of findings regarding efficacy and challenges.

Main Results:

• Combinations of targeted therapies and immunotherapies show potential for synergistic effects.
• Mechanisms include increased tumor antigen presentation and T cell infiltration.
• Clinical application faces challenges related to toxicity and patient selection.

Conclusions:

• Combining targeted therapies with immunotherapies is a promising strategy for improving cancer treatment.
• Further research is needed to optimize combination regimens and overcome clinical hurdles.
• Rational design of these combinations can lead to more effective and durable anti-cancer responses.